InspireMD Inc (NYSEAMERICAN:NSPR) reported the preliminary 24-month follow-up data in the PARADIGM-101 clinical trial using CGuard™ EPS. PARADIGM-101 marks as an investigator-led clinical trial assessing the application of CGuard™ EPS in 101 successive all-comer subjects with high-risk asymptomatic or symptomatic carotid artery stenosis. The report showcased illustrate that no postprocedural or periprocedural intervention related major stroke, myocardial infarction or death had occurred in the trial subjects at 24-month follow-up.
This excellent report in PARADIGM-101 is steady with the other CGuard™ EPS studies, including CARENET, WISSGOTT Study, CASANA Study and IRON-GUARD. The PARADIGM trial long-term preliminary data further validate the sustained advantages of CGuard™ out to 2 years and make it a prospective permanent therapeutic protection alternative for all-comer subject with carotid artery disease.
James Barry, PhD, the CEO of InspireMD, expressed that they are thrilled to see Professor Musialek’s report presented on the long-term follow-up results from the PARADIGM trial, which exhibits the longest identified clinical follow-up with similar carotid devices so far. This is merely another piece of data that remains to reinforce the prospective advantages of CGuard EPS. The 24-month follow-up report from this study simply validates the sustained long term gains CGuard could offer to people with carotid artery disease.
The VEITHsymposium offers interventional cardiologists, interventional radiologists, vascular surgeons, and other vascular experts with an exciting and unique format to learn the latest information about what is important and new in the treatment of vascular disease. This 5-day event showcases rapid-fire presentations from renowned vascular specialists with focus on the latest developments, changing concepts in management and diagnosis, pressing controversies and advanced techniques. The ICI Meeting 2017 marks the leading global conference for developments in cardiovascular systems (brain, peripheral vessels and heart) and high-tech life science firms.
In the last trading session, the stock price of InspireMD declined more than 2% to close the day at $0.16.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of USmarketsDaily.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: